Financial Performance - Net profit attributable to shareholders decreased by 80.17% year-on-year, amounting to CNY 6,117,082.04, primarily due to a decline in revenue caused by the pandemic [19]. - Operating revenue for the period was CNY 276,875,463.42, representing a decrease of 13.82% compared to the same period last year [12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 2,343,106.78, a decrease of 92.33% year-on-year [12]. - Net profit for Q1 2020 was $5.89 million, a decline of 84.5% compared to $37.89 million in Q1 2019 [46]. - The total profit for Q1 2020 was $14.34 million, down 72.6% from $52.38 million in Q1 2019 [44]. - The total comprehensive income for the period was reported at -¥5,059,820.62, compared to -¥9,676,426.99 in the previous year, indicating an improvement in financial performance [55]. Cash Flow - The net cash flow from operating activities was CNY 3,088,365.70, down 39.01% from CNY 5,063,415.77 in the previous year [12]. - Net cash flow from operating activities decreased by 39.01% to 3,088,365.70 from 5,063,415.77, mainly due to reduced cash received from sales [26]. - In Q1 2020, the company reported a net cash flow from operating activities of ¥3,088,365.70, a decrease of 39.1% compared to ¥5,063,415.77 in Q1 2019 [55]. - Total cash inflow from operating activities was ¥305,374,759.16, down from ¥330,905,299.64 in the previous year, reflecting a decline of 7.7% [55]. - The net cash flow from financing activities improved by 26.58% to -13,757,596.89 from -18,738,301.82, as the repayment of loans decreased compared to the previous year [26]. - The net cash flow from financing activities was -4,367,079.95, compared to a positive cash flow of 529,894.61 in the previous period [59]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,878,884,727.41, a decrease of 0.20% compared to the end of the previous year [12]. - Total liabilities amounted to approximately ¥1,405.83 billion, a decrease of 1.5% from ¥1,427.82 billion in the previous period [39]. - Non-current liabilities decreased to 1,330,679,579.61 from 1,350,003,407.69, reflecting a reduction in short-term borrowings [32]. - The total current assets were ¥662.05 million, a decrease of 1.3% from ¥670.43 million [38]. - The total assets decreased slightly to ¥4,197.23 billion from ¥4,209.13 billion, a decline of 0.3% [39]. Equity and Earnings - Basic earnings per share were CNY 0.01, a decrease of 85.71% compared to CNY 0.07 in the previous year [12]. - The weighted average return on equity decreased by 93.00 percentage points to 0.18% [12]. - The total equity attributable to shareholders reached ¥3,366.26 billion, an increase from ¥3,353.70 billion, reflecting a growth of 0.4% [39]. - The company’s total equity reached ¥3,473.05 billion, an increase from ¥3,460.72 billion, reflecting a growth of 0.4% [39]. Expenses - Employee compensation payable decreased by 48.29% to CNY 28,429,704.00, mainly due to the payment of 2019 annual performance bonuses [21]. - Research and development expenses increased to $27.90 million in Q1 2020, up 16.4% from $23.99 million in Q1 2019 [44]. - The company experienced a decrease in sales expenses to $59.72 million in Q1 2020 from $64.30 million in Q1 2019, a reduction of 7.9% [44]. - The company’s financial expenses decreased significantly to $248.86 thousand in Q1 2020 from $2.64 million in Q1 2019, a decline of 90.6% [44]. Investments - Investment income rose by 126.98% to 1,415,829.71 from -5,246,871.58, attributed to gains from the disposal of financial assets [23]. - The company reported an investment income of $1.42 million in Q1 2020, a significant improvement from a loss of $5.25 million in Q1 2019 [44]. - The company received ¥400,588,000.00 from investment recoveries in Q1 2020, indicating strong investment performance [55]. Accounting Standards - The company implemented new revenue and leasing standards starting January 1, 2020, which are not expected to significantly impact revenue recognition or financial metrics [59]. - The company did not make any retrospective adjustments to prior financial statements due to the new accounting standards [60]. - The company’s total assets and net assets are not expected to be significantly affected by the new accounting standards [59].

Financial Performance - The company achieved operating revenue of RMB 1,005,353,917.75, representing a year-on-year increase of 3.50%[26] - The net profit attributable to shareholders was RMB 93,502,355.08, a decrease of 72.05% compared to the same period last year[26] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 71,669,807.52, an increase of 390.57% year-on-year[26] - Basic and diluted earnings per share were both RMB 0.21, down 75.00% from the previous year[18] - The major reason for the decline in net profit was the previous year's recognition of investment income of RMB 260 million from the disposal of equity stakes in certain companies[26] - The company reclassified the performance of Shanghai Aoyuan Medical Supplies Co., Ltd. from non-recurring to regular income, contributing to the increase in net profit after deducting non-recurring gains and losses[26] Assets and Liabilities - The total assets at the end of the reporting period were RMB 4,945,528,004.99, an increase of 11.30% from the end of the previous year[18] - The total liabilities amounted to ¥1,467,715,807.94, a marginal increase of 0.2% from ¥1,459,016,323.62[44] - The equity attributable to shareholders increased to ¥3,350,953,261.27 from ¥2,772,549,620.35, marking a growth of 21.0%[44] - The total non-current assets decreased slightly to ¥3,026,663,113.19 from ¥3,054,727,840.37, a decline of 0.9%[42] Cash Flow - The net cash flow from operating activities for the year-to-date was RMB 156,699,220.70, a significant increase of 197.11% compared to the same period last year[18] - Net cash flow from operating activities increased by 197.11% compared to the same period last year, mainly due to increased cash received from sales of goods and services[30] - Cash inflow from financing activities amounted to CNY 455,854,254.82, with a net cash flow of CNY 352,456,237.59, contrasting with a net outflow of -CNY 58,545,107.03 last year[77] - The total cash and cash equivalents at the end of the period reached CNY 990,675,535.57, up from CNY 528,418,247.77 in the previous year[77] Shareholder Information - The company reported a total of 37,349 shareholders at the end of the reporting period[21] Other Income and Expenses - Other income increased by 827.05% compared to the same period last year, primarily due to an increase in government subsidies[30] - R&D expenses increased to approximately ¥27 million in Q3 2019 from ¥20 million in Q3 2018, reflecting a growth of 35.5%[54] - The management expenses for Q3 2019 were approximately ¥8.08 million, down from ¥22.69 million in Q3 2018, representing a decrease of 64.4%[69] - The financial expenses for Q3 2019 were approximately ¥2.35 million, slightly up from ¥2.32 million in Q3 2018, indicating a marginal increase of 1.3%[69] Investment Activities - Cash outflow from investment activities totaled CNY 120,768,612.47, compared to CNY 283,907,544.68 in the previous year, resulting in a net cash flow from investment activities of -CNY 104,003,678.31[77] - Investment income decreased by 104.54% compared to the same period last year, mainly due to the disposal of equity stakes in certain companies in the previous year[30] Profitability - The company reported a net loss of ¥-537,712,431.24, an improvement from a loss of ¥-631,214,786.32 in the previous year[44] - The total operating profit for the first three quarters of 2019 was a loss of approximately ¥32.21 million, compared to a profit of ¥75.69 million in the same period of 2018, indicating a decline in profitability[69] - The company reported a net loss of approximately ¥5.62 million for Q3 2019, compared to a net loss of ¥6.67 million in Q3 2018, showing an improvement of 15.7%[69] Current Assets - As of September 30, 2019, the total current assets amounted to ¥1,918,864,891.80, an increase of 38.1% from ¥1,388,699,383.72 on December 31, 2018[38] - Accounts receivable rose to ¥461,871,120.97, up 11.2% from ¥415,330,742.05 in the previous year[38] - Cash received from sales and services was CNY 1,073,303,101.58, an increase from CNY 974,117,792.01 year-over-year[75]

Financial Performance - The company achieved operating revenue of RMB 668.33 million in the first half of 2019, representing a 3.81% increase compared to the same period last year[20]. - The net profit attributable to shareholders of the listed company was RMB 63.13 million, a decrease of 79.72% year-on-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 51.08 million, an increase of 507.64% compared to the previous year[20]. - The company's cash flow from operating activities was RMB 93.45 million, up 130.90% year-on-year[20]. - Basic earnings per share were RMB 0.14, down 82.72% from RMB 0.81 in the same period last year[23]. - The weighted average return on net assets decreased by 8.53 percentage points to 2.24%[23]. - The total assets of the company at the end of the reporting period were RMB 4.48 billion, an increase of 0.90% from the previous year[22]. - The net assets attributable to shareholders of the listed company were RMB 2.87 billion, up 3.56% from the previous year[22]. - The significant decline in net profit was primarily due to the previous year's gain from the disposal of equity in certain subsidiaries amounting to RMB 260 million[23]. - The increase in net profit after deducting non-recurring gains and losses was mainly attributed to the merger with Shanghai Aoyuan, which expanded the consolidation scope[23]. Business Operations - The company is engaged in cell detection preparation and storage, gene testing, and the research, production, and sales of in vitro diagnostic reagents and instruments, focusing on two core areas: cell storage and application, and in vitro diagnostic reagents[29]. - The company has established a nationwide cell resource library covering over 2/3 of regions and 3/4 of the population in China, providing services for umbilical cord blood stem cells and other cell types[32]. - The company completed the acquisition of Shanghai Aoyuan and its subsidiaries, forming a biopharmaceutical group with five major business segments, enhancing its market presence and operational capabilities[32]. - The newborn division focuses on the detection, preparation, and storage of umbilical cord blood stem cells, with a comprehensive service network across multiple provinces[32]. - The adult division provides immune cell and mesenchymal stem cell storage services, targeting health-conscious adults and research institutions[32]. - The gene division offers genomic medical testing services and reagent sales, utilizing both self-operated and agency marketing models to establish sales channels[32]. - The company’s proprietary biochemical diagnostic reagent brand "DENUO" includes a wide range of testing projects across nine major series, making it one of the most comprehensive manufacturers in the domestic market[32]. - The company has established 4 Life Science Museums nationwide to enhance public awareness of life science technologies, with over 1,800 applications of umbilical cord blood stem cells recorded by June 30, 2019[35]. - The launch of the new online health management platform "Lifebank" integrates sales, operations, and services for users of all ages, facilitating the collaborative sales of various health products[35]. Research and Development - The company emphasizes research and development, with over 157 R&D personnel, including 56 with master's degrees or higher, to maintain product competitiveness[43]. - The company reported a 16.78% increase in R&D expenses, totaling ¥49,033,456.58, reflecting its commitment to innovation and product development[49]. - The company is actively promoting public understanding of life sciences and has increased technical service support for umbilical cord blood stem cell public banks[35]. - Two new approved clinical research projects for stem cells were initiated, including a randomized controlled study for treating hepatitis B cirrhosis and a clinical study on liver regeneration in decompensated cirrhosis patients[35]. - By the end of June 2019, the number of registered stem cell clinical research institutions in China increased to 104, with 51 registered projects covering various diseases[35]. Market and Competitive Landscape - The company has a strong brand presence, being one of the earliest investors in biorepository projects in China, with over 18 years of safe operation and a leading market position in stem cell storage[40]. - The company has developed a comprehensive marketing network, combining direct sales and distributor channels to enhance competitiveness in the market[43]. - The Chinese biopharmaceutical industry continues to grow at a medium to high speed, supported by favorable government policies and an increasing number of enterprises[35]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of 2024[104]. Financial Position and Investments - The company reported a significant increase in other income by 229.07% to ¥1,017,441.70, mainly due to increased government subsidies[49]. - The investment income decreased by 104.64% to -¥11,673,542.84, primarily due to the previous year's gains from equity disposals[49]. - The company made an equity investment of 14,502.48 million yuan during the reporting period, an increase of 93.48% year-on-year[61]. - The company has completed the valuation and capital increase of CAR-T technology, valued at 66 million yuan, with an investment of 58 million yuan in Huyuan Biotechnology[124]. - The company holds a 21.642% stake in Huyuan Biotechnology after the capital increase[124]. Shareholder and Governance Matters - The company has committed to a net profit of no less than 65 million yuan for the year 2018, 79 million yuan for 2019, and 96 million yuan for 2020, with compensation obligations if these targets are not met[94]. - The lock-up period for shares acquired by Shenzhen Jiadao Investment Enterprise (Limited Partnership) is set for 36 months from the end of the issuance, starting from August 27, 2018, to August 26, 2021[93]. - The company’s actual controller and shareholders have committed not to engage in any business that competes with the company or its subsidiaries, both directly and indirectly[91]. - The company has established a long-term commitment to avoid related party transactions with companies under the actual control of De Yuan Investment Company, ensuring fair and reasonable pricing[97]. - The company has confirmed that it will not engage in similar business activities in new business areas that the company may enter in the future[96]. Legal and Compliance Issues - The company has no significant litigation or arbitration matters during the reporting period[115]. - The company has a history of legal disputes regarding land use rights, with a significant judgment requiring repayment of RMB 71.21 million[115]. - The company has reached a settlement in a dispute over a 67% equity transfer, with a payment of RMB 1 million due by December 31, 2018[115]. - The company has received a total of 2.1 million yuan related to the equity transfer, with 29 million yuan still outstanding from Guangzhou Dasai Company[118]. - As of the report date, the company has applied for enforcement of 60 million yuan against Guangzhou Dasai Company due to non-payment[118]. Financial Reporting Changes - The company implemented new financial instrument standards starting January 1, 2019, affecting accounting policies[138]. - Financial assets will be measured at amortized cost or fair value under the new standards[138]. - The company will not retrospectively adjust comparative statements for the previous year due to the new financial instrument standards[139]. Environmental and Social Responsibility - The company is committed to complying with environmental protection laws and regulations[133]. - The company has established management and emergency response plans to ensure compliance with waste discharge standards[133].

证券代码：600645 证券简称：中源协和 公告编号：2019-038 中源协和细胞基因工程股份有限公司 关于举行"投资者网上集体接待日"活动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●召开时间：2019年5月9日（星期四）15：00-16:30 ●召开方式：网络方式召开 一、说明会类型 中源协和细胞基因工程股份有限公司（以下简称"公司"）于2019年4月30 日发布了2018年年度报告。为便于广大投资者更深入全面地了解公司情况，公司 将在全景网以网络方式举行"投资者网上集体接待日"活动。 二、召开时间和方式 时间：2019年5月9日（星期四）15：00-16:30 方式：网络方式召开 三、公司出席人员 公司出席本次"投资者网上集体接待日"活动的人员有：公司副董事长、总 经理李德福先生，董事、常务副总经理李旭先生，副总经理、董事会秘书杨新喆 先生，财务总监王鹏先生（如有特殊情况，出席人员会有调整）。 四、投资者参加方式 投资者可以登录" 全景·路演天下"（http://rs.p5w.net）参 ...

Financial Performance - Net profit attributable to shareholders of the listed company was ¥30,843,567.35, representing a significant decrease of 76.89% year-on-year[12]. - Operating income for the period was ¥321,260,490.79, showing a minor decline of 0.09% compared to the same period last year[12]. - The company reported a basic earnings per share of ¥0.07, reflecting an 80.00% decrease compared to the previous year[12]. - The company reported a net loss attributable to shareholders of ¥600,371,218.97, compared to a loss of ¥631,214,786.32 in the previous period[41]. - Net profit for Q1 2019 was RMB 37,888,824.89, a decrease of 72.6% from RMB 138,037,230.47 in Q1 2018[51]. - Total profit for Q1 2019 was RMB 52,376,988.47, down from RMB 150,593,066.09 in Q1 2018, indicating a challenging financial environment[51]. - The company reported a significant drop in investment income, with a loss of RMB 5,246,871.58 compared to a gain of RMB 103,555,184.59 in the same period last year[50]. Cash Flow - The net cash flow from operating activities was ¥5,063,415.77, a substantial improvement from a negative cash flow of ¥37,777.41 in the previous year[12]. - Net cash flow from operating activities for Q1 2019 was ¥5,063,415.77, compared to a negative cash flow of ¥37,777.41 in Q1 2018, indicating a significant improvement[61]. - Total cash inflow from operating activities was ¥330,905,299.64, while cash outflow was ¥325,841,883.87, resulting in a net cash flow of ¥5,063,415.77[61]. - The net cash flow from investing activities was -20,827,988.33 RMB, a significant decrease compared to 70,540,368.00 RMB in the previous period[66]. - Cash inflow from financing activities was ¥10,854,332.75, while cash outflow was ¥29,592,634.57, leading to a net cash flow of -¥18,738,301.82 from financing activities[63]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,445,925,648.48, a slight increase of 0.06% compared to the end of the previous year[12]. - Total liabilities amounted to ¥1,430,023,112.26, a decrease from ¥1,459,016,323.62[41]. - The company's total liabilities decreased to approximately 1.257 billion yuan from 1.268 billion yuan year-over-year[39]. - The total current assets reached 1,388,699,383.72 RMB, reflecting the company's liquidity position[69]. - The total non-current assets were reported at 3,054,727,840.37 RMB, contributing to a total asset value of 4,443,427,224.09 RMB[69]. Shareholder Information - The number of shareholders at the end of the reporting period was 41,672, with the largest shareholder holding 18.93% of the shares[15]. - Total equity reached ¥3,015,902,536.22, an increase from ¥2,984,410,900.47[41]. - Total equity attributable to shareholders decreased to ¥2,670,594,429.97 from ¥2,680,270,856.96[46]. - Total equity attributable to the parent company is approximately ¥2.77 billion[74]. Expenses and Costs - Financial expenses increased by 41.37% compared to the same period last year, primarily due to a decrease in interest income from deposits[22]. - Research and development expenses increased to RMB 23,987,768.53, up from RMB 22,703,712.22 in Q1 2018, indicating a focus on innovation[50]. - The company experienced a decrease in sales expenses, which were RMB 64,299,323.74 compared to RMB 71,485,155.34 in the previous year, reflecting cost control measures[50]. - Total operating costs amounted to RMB 264,002,616.04, with operating costs specifically at RMB 95,878,345.95, down from RMB 102,403,427.81 in the previous year[50]. Other Income and Gains - The net profit after deducting non-recurring gains and losses was ¥30,565,735.20, a significant increase of 691.92% year-on-year[12]. - Other income rose by 97.63% compared to the previous year, attributed to an increase in government subsidies[22]. - Asset impairment losses surged by 217.79% year-on-year, mainly due to the provision for bad debts[22]. Investments and Acquisitions - The company agreed to transfer 67% equity of Zhejiang SaiShang Pharmaceutical Technology Co. for 60 million RMB, with a settlement agreement reached for 30 million RMB[28]. - The company approved a capital increase in Huyuan Biotechnology (Tianjin) Co., valuing the CAR-T technology at 58 million RMB[28]. - The company approved a proposal for its subsidiary to acquire a total of 24.14% equity in Wuxi Aorui Dongyuan Biotechnology Co., Ltd. for no more than 66.11 million yuan, with specific amounts of 47.21 million yuan and 18.90 million yuan allocated for different equity stakes[31].

Financial Performance - The audited net profit for the parent company in 2018 was RMB 33.93 million, with accumulated undistributed profits as of December 31, 2018, amounting to -RMB 175 million[4]. - The company's operating revenue for 2018 was approximately ¥1.32 billion, a slight decrease of 0.02% compared to 2017[22]. - Net profit attributable to shareholders for 2018 was approximately ¥59.25 million, representing a significant increase of 471.58% year-over-year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 1,296.39% compared to the previous year, primarily due to goodwill impairment losses[24]. - Basic earnings per share for 2018 were ¥0.15, a 400% increase from ¥0.03 in 2017[24]. - The weighted average return on equity for 2018 was 2.18%, an increase of 1.79 percentage points compared to 2017[24]. - The company generated a net cash flow from operating activities of approximately ¥130.08 million in 2018, an increase of 24.60% from the previous year[22]. - Non-recurring gains for 2018 totaled approximately ¥321.73 million, significantly higher than the previous year's gains[32]. - The company reported a net profit of approximately ¥133.48 million in Q1 2018, with a notable decline in Q4 resulting in a net loss of approximately ¥275.30 million[30]. - The company achieved a revenue of RMB 1.32 billion in the reporting period, a slight decrease of 0.02% compared to the previous year[60]. - Net profit attributable to shareholders reached RMB 59.25 million, representing a significant increase of 471.58% year-on-year, primarily due to a gain of RMB 260 million from the disposal of equity stakes in Beijing Pan Genomics and Beijing San You Li He Ze Biotechnology[60]. Asset and Investment Overview - The company's total assets at the end of 2018 were approximately ¥4.44 billion, reflecting a 0.64% increase from the previous year[22]. - The company's available-for-sale financial assets increased by 36.35% compared to the previous period, amounting to ¥307,866,380.71, which represents 6.93% of total assets[47]. - Investment properties rose by 68.78% from the previous period, totaling ¥157,750,673.03, accounting for 3.55% of total assets[47]. - The overseas assets of the company amounted to ¥481,628,032.08, representing 10.84% of total assets[47]. - The company has a total of 163,337,005.68 yuan in assets under restriction due to mortgage loans[95]. - The company has provided guarantees with joint liability for various projects, indicating a commitment to support its subsidiaries[198]. Research and Development - The company invested approximately RMB 103.3 million in research and development during the reporting period, focusing on innovation and product line expansion[37]. - R&D investment accounted for 7.82% of the company's total revenue in 2018, with over 157 R&D personnel, including 56 with master's degrees or higher[51]. - The company completed 48 stem cell research and product development projects, with 3 completed and 4 halted[82]. - The company launched the "Yuanwei Kang Disease Full Item Genetic Susceptibility Gene Detection" product, utilizing a chip developed in collaboration with Illumina, specifically designed for the East Asian population[51]. Market and Business Expansion - The company has established cell resource banks in 18 provinces, covering over 2/3 of the regions and 3/4 of the population in China, with more than 300,000 stored units accumulated over 18 years[35]. - The company has developed a national marketing network for cell detection and storage services, as well as a distributor-based network for in vitro diagnostic reagents, enhancing its sales capabilities[37]. - The company aims to leverage synergies between its business segments to mitigate risks associated with fluctuations in specific industries, ensuring sustainable growth[35]. - The company is expanding its cell storage offerings, including adult cell storage for immune and adipose stem cells, while maintaining its leadership in the newborn stem cell storage market[41]. - The company plans to enhance market penetration through new media marketing and e-commerce, leveraging its "life bank" resources[123]. Regulatory and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[4]. - The company has not proposed any profit distribution plan or capital reserve transfer plan for the 2018 fiscal year, pending approval at the annual shareholders' meeting[4]. - The company has commitments regarding share lock-up periods, with certain shareholders restricted from trading their shares for 36 months post-issuance[140]. - The company has a plan for share repurchase that is not applicable for cash dividends[137]. - The company has established a commitment to avoid and minimize related party transactions post-restructuring, ensuring fair operations at market prices[156]. Risks and Challenges - The company has detailed the risk factors it faces in the report, which can be found in the section discussing operational conditions[4]. - The company faces risks related to industry policies, technology, talent retention, quality management, and exchange rate fluctuations[130]. - In 2018, the national newborn birth rate dropped to 15.16 million, a 12% decrease from 17.23 million in 2017, impacting storage business negatively; however, the overall stem cell storage rate in China remains below 1%, indicating significant growth potential[41]. Shareholder Commitments - The company has committed to achieving a net profit of no less than 65 million yuan, 79 million yuan, and 96 million yuan for the years 2018, 2019, and 2020 respectively[145]. - The company guarantees that there will be no direct or indirect competition with Zhongyuan Xiehe and its subsidiaries in the future[145]. - The company will ensure compliance with all relevant regulations and will not exploit its shareholder position for undue benefits[148]. Legal and Audit Matters - The company is involved in significant litigation, including a case against Singapore Huide Investment Holdings for a land use rights dispute, with a judgment requiring repayment of 71.21 million yuan[171]. - The company has not faced any significant accounting errors or non-standard audit opinions during the reporting period[164]. - The audit fee for the company in 2018 was adjusted to 2.2 million yuan, including 500,000 yuan for internal control audit[168].

Financial Performance - Net profit attributable to shareholders increased significantly by 1,116.90% to CNY 334,556,709.91 for the first nine months of the year[6] - Operating revenue for the first nine months rose by 1.23% to CNY 971,345,455.23 compared to the same period last year[6] - Basic and diluted earnings per share both increased to CNY 0.84, up 1,100.00% compared to the previous year[7] - The net profit attributable to shareholders increased by 1116.90% year-on-year, while the net profit excluding non-recurring gains and losses rose by 489.84%[11] - The company reported a net loss of ¥379,077,509.64, an improvement from a loss of ¥713,634,219.55 in the previous period[21] - Total revenue for Q3 2018 was CNY 327,526,831.54, a slight increase from CNY 322,365,607.18 in Q3 2017, representing a growth of approximately 1.0%[28] - Net profit for Q3 2018 was CNY 26,459,807.02, down from CNY 31,887,216.87 in Q3 2017, reflecting a decrease of approximately 17.5%[29] - The total profit for the first nine months was 75,690,044.25 CNY, a recovery from a loss of -75,037,435.90 CNY in the same period last year[33] Assets and Liabilities - Total assets increased by 6.45% to CNY 4,659,152,934.87 compared to the end of the previous year[6] - The company has seen a significant increase in net assets attributable to shareholders, which rose by 10.71% to CNY 3,010,338,786.55 compared to the end of the previous year[6] - The company's total liabilities decreased slightly from ¥1,456,054,959.55 to ¥1,432,049,376.87, a reduction of approximately 1.6%[21] - Total assets as of Q3 2018 amounted to CNY 3,711,084,690.31, up from CNY 2,390,798,819.82 in the previous year, marking an increase of about 55.3%[25] - Total liabilities for Q3 2018 were CNY 1,007,639,249.56, compared to CNY 989,345,944.45 in Q3 2017, showing a slight increase of approximately 1.3%[25] - Owner's equity totaled CNY 2,703,445,440.75 in Q3 2018, significantly higher than CNY 1,401,452,875.37 in Q3 2017, representing an increase of about 92.9%[25] Cash Flow - The net cash flow from operating activities decreased by 28.92% to CNY 52,741,574.36 for the first nine months[6] - The company's cash flow from operating activities decreased by 28.92% to CNY 52,741,574.36, mainly due to increased employee compensation payments[13] - The net cash flow from investing activities increased by 126.99% to CNY 43,906,566.97, attributed to the proceeds from the disposal of stakes in certain companies[13] - Operating cash inflow for the year-to-date period reached ¥1,071,912,480.39, a slight increase from ¥1,035,835,289.87 in the previous year, reflecting a growth of approximately 3.7%[35] - Net cash flow from operating activities decreased to ¥52,741,574.36 from ¥74,201,546.04, indicating a decline of about 29% year-over-year[35] - Investment cash inflow totaled ¥327,814,111.65, down significantly from ¥786,005,373.69, representing a decrease of approximately 58%[36] - Cash flow from financing activities showed a net outflow of ¥58,545,107.03 compared to a net inflow of ¥106,836,063.81 in the previous year, indicating a shift in financing strategy[36] Shareholder Information - The total number of shareholders reached 45,024 by the end of the reporting period[9] - The largest shareholder, Tianjin Development Zone Deyuan Investment Development Co., Ltd., holds 18.93% of the shares[10] - The company plans to increase its shareholding by at least 2% and up to 3% of the total issued shares, extending the implementation period of this plan to November 2, 2018[16] Investments and Acquisitions - Investment income reached CNY 268,289,285.52, reflecting a significant increase of 3873.07% compared to the same period last year due to the disposal of stakes in Beijing Fan Sheng Zi Gene Technology Co., Ltd. and Beijing San You Li He Ze Biotechnology Co., Ltd.[12] - The company completed the acquisition of Shanghai Ao Yuan Medical Supplies Co., Ltd. and expanded its consolidation scope during the reporting period[14] - The company plans to transfer 67% of its stake in Zhejiang Sai Shang Pharmaceutical Technology Co., Ltd. for CNY 60 million, which has been approved by the shareholders' meeting[13] Other Financial Metrics - The company reported non-operating income of CNY 17,118,424.78 for the current period, contributing to overall profitability[8] - Other comprehensive income rose by 92.96% to CNY 38,623,918.26, mainly due to an increase in foreign currency translation differences[12] - The company incurred management expenses of 41,923,089.91 CNY for the first nine months, up from 31,155,002.43 CNY year-on-year[31] - The financial expenses for the first nine months were 4,465,866.96 CNY, down from 6,830,766.01 CNY in the previous year[31] - The company reported a tax expense of 0.38 CNY in the third quarter, indicating minimal tax liabilities[33] - The company received tax refunds amounting to ¥4,510,040.82, an increase from ¥3,280,312.50, showing improved tax recovery efforts[35]

Financial Performance - The company's operating revenue for the first half of 2018 was approximately RMB 424.13 million, representing a year-on-year increase of 3.92% compared to RMB 408.12 million in the same period last year[19]. - The net profit attributable to shareholders of the listed company surged to approximately RMB 270.21 million, a significant increase of 3,121.37% from RMB 8.39 million in the previous year[19]. - The company's net assets attributable to shareholders reached approximately RMB 1.73 billion, reflecting a growth of 14.94% compared to RMB 1.51 billion at the end of the previous year[19]. - The total assets of the company increased to approximately RMB 3.20 billion, marking a 6.76% rise from RMB 3.00 billion at the end of the previous year[19]. - Basic earnings per share for the reporting period were RMB 0.70, a substantial increase of 3,400% compared to RMB 0.02 in the same period last year[20]. - The weighted average return on net assets rose to 16.67%, an increase of 16.12 percentage points from 0.55% in the previous year[21]. - The net cash flow from operating activities was negative at approximately RMB -8.85 million, an improvement from RMB -20.34 million in the previous year[19]. - The company reported a total of RMB 261.80 million in non-recurring gains and losses, primarily from fair value changes in financial assets[23]. Business Operations - The company's cell preparation and storage business generated revenue of 248 million yuan, an increase of 5.76% year-on-year[29]. - The gene testing business achieved revenue of 50.3 million yuan, reflecting a growth of 25.32% compared to the previous year[29]. - The company has established cell resource banks in multiple provinces, including Tianjin, Heilongjiang, and Jiangsu, enhancing its position in the upstream cell technology field[30]. - The company is actively preparing for the application of stem cell and immune cell drugs, collaborating with major hospitals for clinical research[30]. - The company has adopted a "cell + gene" dual-core strategy to drive its precision medicine layout, aiming to maximize shareholder value[27]. - The marketing network for in vitro diagnostic products has expanded across most provinces, excluding Hong Kong, Macau, and Tibet, ensuring broad coverage to end customers[28]. - The company is focusing on integrating quality assets and streamlining its business lines to enhance operational efficiency[27]. Industry Trends - National policies have been increasingly supportive of the stem cell and gene testing industries, promoting rapid development in these fields[31]. - The domestic stem cell storage market is estimated to exceed 30 billion RMB, with a current storage rate of less than 1% compared to developed countries, indicating significant growth potential[34]. - The CAR-T therapy market is rapidly expanding, with Celgene's acquisition of Juno for $9 billion highlighting the industry's growth potential[38]. - As of July 2018, China has registered 151 CAR-T projects, nearly double that of the US, indicating a strong research presence in this field[39]. Investments and Acquisitions - The company confirmed an investment income of RMB 260 million from the disposal of partial equity in Beijing Fan Shengzi Gene Technology Co., Ltd. and Beijing San You Li He Ze Biotechnology Co., Ltd.[21]. - The company plans to acquire 100% equity of Shanghai Aoyuan Company to enhance its comprehensive diagnostic business layout, having received approval from the China Securities Regulatory Commission[44]. - The company completed the acquisition of 100% equity in Shanghai Aoyuan Company, with the transaction approved by the second extraordinary general meeting of shareholders in 2018[86]. - The company made a significant investment by acquiring a 28% partnership interest in Shenzhen Yingtai Hongkang Venture Capital Partnership for RMB 70 million, with the second phase of the capital contribution completed in March 2018[88]. Shareholder and Governance Matters - The company has not proposed any profit distribution plan or capital reserve transfer to increase share capital for the reporting period[6]. - The company has made commitments to avoid engaging in any business that competes directly or indirectly with its subsidiaries, ensuring the protection of shareholder interests[75]. - The company has committed to fair and transparent practices in any related party transactions to protect shareholder interests[77]. - The company has a robust governance framework to ensure compliance with relevant laws and regulations[77]. - The company has not faced any penalties or corrective actions related to integrity issues during the reporting period[80]. Legal and Compliance Issues - The company is involved in a lawsuit seeking RMB 50 million in overdue payment and RMB 1.05 million in late fees related to a 67% equity transfer dispute[79]. - The company has a legal judgment requiring a repayment of RMB 71.21 million from a previous case, which has been upheld by the court[79]. - The company maintains a complete independent operational system and governance structure post-equity changes, ensuring no substantial impact on its operational capabilities[77]. Financial Position and Assets - The total equity attributable to the parent company at the end of the period was approximately $1.87 billion, showing a decrease from $1.63 billion at the end of the previous period[137]. - The company reported a significant increase in cash inflow from the disposal of subsidiaries, amounting to $125 million, which was not present in the previous period[134]. - The company’s total liabilities decreased, reflecting improved financial stability and management of debt obligations[134]. - The company reported a total guarantee amount of 1.904 billion RMB, which accounts for 10.98% of the company's net assets[93]. Accounting and Financial Reporting - The financial statements are prepared based on the going concern assumption and comply with the relevant accounting standards[157]. - The company recognizes deferred tax assets related to deductible temporary differences if new information indicates that the economic benefits can be realized within 12 months post-acquisition, reducing goodwill accordingly[163]. - The company employs valuation techniques for financial instruments without active markets, including recent market transactions and discounted cash flow methods[173]. - The company assesses impairment losses for loans and receivables based on the present value of expected future cash flows[178]. Employee and Stock Matters - The company repurchased and canceled a total of 212.8 million shares of restricted stock, with 177.8 million shares canceled by February 14, 2018, and 32.2 million shares canceled by June 6, 2018[81]. - The first phase of the employee stock ownership plan involved the purchase of 2,540,100 shares at a total cost of approximately RMB 87 million, averaging RMB 34.25 per share, representing 0.66% of the company's total share capital[82]. - The first phase of the employee stock ownership plan was extended until March 31, 2019, but was terminated after all shares were sold by June 25, 2018, due to regulatory and market conditions[84].

Financial Performance - The company's audited net profit for 2017 was -38.14 million RMB, resulting in a cumulative undistributed profit of -209 million RMB as of December 31, 2017, leading to no profit distribution to shareholders[5]. - Operating revenue for 2017 was 870.91 million RMB, representing a 3.94% increase compared to 837.90 million RMB in 2016[21]. - The net loss attributable to shareholders for 2017 was -18.46 million RMB, a decrease of 148.76% from a profit of 37.86 million RMB in 2016[22]. - The net cash flow from operating activities was 70.27 million RMB, down 51.09% from 143.67 million RMB in 2016[22]. - Total assets as of the end of 2017 were 2.99 billion RMB, a slight decrease of 0.12% from 3.00 billion RMB in 2016[22]. - The net assets attributable to shareholders decreased by 4.96% to 1.51 billion RMB from 1.59 billion RMB in 2016[22]. - Basic earnings per share decreased by 150% compared to the previous year, from 0.10 to -0.05 RMB[23]. - The weighted average return on equity dropped by 3.64 percentage points to -1.23%[23]. - The company reported a net profit of -64.43 million RMB for 2016 and -38.14 million RMB for 2017, with cumulative undistributed profits of -209 million RMB as of December 31, 2017, resulting in no profit distribution to shareholders[112]. Business Operations - The company’s main business includes cell preparation and storage services, gene testing, and sales of in vitro diagnostic reagents[32]. - The company operates under a division + direct management model, promoting independent accounting and resource integration across business units[33]. - The company achieved operating revenue of 871 million RMB, a year-on-year increase of 3.94%[47]. - The company plans to acquire 100% equity of Shanghai Aoyuan Medical Supplies Co., enhancing industry integration and core competitiveness[43]. - The company is in the process of responding to feedback from the China Securities Regulatory Commission regarding its major asset restructuring application[44]. - The company is focusing on enhancing brand awareness through various media channels and hosting events like the "Zhongyuan Xiehe Life Medicine Award" ceremony[45]. - The company plans to expand its market presence and enhance its product offerings in the coming year[55]. - The establishment of Wuhan Guanggu Zhongyuan Co. contributed to the overall revenue growth, marking a strategic expansion[56]. Research and Development - Research and development expenses rose by 43.11% to 67.11 million RMB[50]. - The company completed 16 out of 44 stem cell research and product development projects during the reporting period[63]. - The company has established a key expert group for "Stem Cell and Translational Research" to ensure the successful implementation of national key R&D projects[88]. - The company is committed to developing a wide range of testing projects and strengthening collaborations with internationally renowned institutions to provide competitive testing services[103]. - The company will continue to push forward with research and development projects and actively pursue drug approvals in both domestic and international markets[105]. Market Trends and Strategy - The global stem cell storage market is projected to reach $18.16 billion by 2018, with a compound annual growth rate (CAGR) of 21% from 2015 to 2018[92]. - The domestic stem cell storage rate is currently below 1%, indicating significant growth potential, with an estimated market size exceeding $30 billion[93]. - The approval of the first CAR-T cell therapy, Kymriah, priced at $475,000, marks a significant milestone in the commercialization of CAR-T products[96]. - The immune cell therapy sector is recognized as a key area for development, with policies supporting its growth across multiple regions in China[90]. - The company aims to secure its leading position in the immune cell field by actively applying for CAR-T drug approvals, leveraging proprietary technology and clinical application advantages[97]. Corporate Governance and Compliance - The company has established a commitment to fair and transparent dealings in any necessary related transactions with controlling shareholders[116]. - The company has confirmed that it will not require any illegal guarantees from its controlling shareholders[116]. - The company has maintained a governance structure that complies with relevant laws and regulations, ensuring the protection of shareholder rights[189]. - The company has no recent penalties from securities regulatory agencies, indicating compliance with regulations[183]. - The board of directors consists of 9 members, including 3 independent directors, complying with legal regulations and the company's articles of association[190]. Shareholder and Equity Management - The company has not distributed any dividends in the last three years, with a net profit of -18.46 million RMB in 2017[112]. - The total number of ordinary shares decreased from 386,091,314 to 386,081,314 due to the repurchase and cancellation of 10,000 restricted shares[152]. - The number of shareholders increased from 41,885 to 44,607 during the reporting period[159]. - The company has a commitment to maintain a 30-month lock-up period for newly issued shares, ensuring stability in shareholding[165]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 7.0953 million yuan[181]. Employee Management and Development - The total number of employees in the parent company and major subsidiaries is 1,981, with 931 in sales, 420 in production, and 281 in technical roles[184]. - The company has implemented a performance evaluation and compensation system for senior management, which was approved by the board of directors[181]. - A training program has been established to improve employee skills, including a special training project for mid-to-senior management called the "Blackstone Plan"[186]. - The company is focusing on enhancing its compensation and benefits system to attract and retain talent, particularly for core business personnel[185]. Financial Management and Investments - The company has made a significant equity investment of ¥12,834.40 million (100%) in Concord East China Stem Cell Gene Engineering Co., Ltd. for a 20-year term[75]. - The company holds a total of 172 authorized patents, ensuring its competitive edge in research and clinical transformation[40]. - The company has received approval for 172 patents, with 17 new patents granted in 2017[45]. - The company has implemented an employee stock ownership plan, purchasing 2,540,100 shares for a total of RMB 87,002,663.34, with an average price of approximately RMB 34.25 per share[127]. - The total investment amount during the reporting period was 263.14 million, reflecting a decrease of 37.38% compared to the previous year[74].

2018 年第一季度报告 公司代码：600645 公司简称：中源协和 中源协和细胞基因工程股份有限公司 2018 年第一季度报告 1 / 20 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 10 | 2018 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上 年度末增减(%) | | | | --- | --- | --- | --- | --- | --- | | 总资产 | 3,032,917,089.85 | 2,999,979,976.43 | 1.10 | | | | 归属于上市公司股东的 | 1,576,278,763.77 | 1,509,015,295.94 | 4.46 | | | | 净资产 | | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减 | | | | | | | (%) | | | | 经营活动产生的现金流 | -27,471,358.58 ...